Summit Corporation plc (Summit) is a United Kingdom-based drug discovery and development company. The Company is engaged in developing drug candidates to treat Duchenne Muscular Dystrophy (DMD), a fatal genetic disease, and Clostridium difficile Infection (CDI), an infectious disease. The Company is advancing a broad pipeline of utrophin modulators that comprise its lead candidate SMT C1100 and next generation modulators that are at an earlier stage of development. It is in a Phase 1b clinical trial. The Company is developing SMT19969 as a differentiated, novel antibiotic that is a potential treatment for initial CDI that could significantly reduce rates of recurrent disease. SMT19969 completed a Phase 1 clinical trial in healthy volunteers with the results showing it to be safe and well tolerated at all doses tested, including the expected therapeutic dose. The Company�s subsidiaries include Summit (Oxford) Limited and Summit (Wales) Limited.